Northeastern receives $1.5M NIH grant to study nanocarrier-based pharmaceuticals

October 23, 2008: Vladimir Torchilin, professor and chair of the department of pharmaceutical sciences at Northeastern University’s Bouvé College of Health Sciences, was recently awarded a 5-year, $1.54 million grant from the National Institutes of Health‘s (NIH) National Cancer Institute to investigate ways to increase the efficacy of nanocarrier-based pharmaceuticals for drug and gene therapy. Many pharmaceutical agents, such as drugs or DNA, need to enter the cell to carry out their therapeutic properties, and this study will address the challenges of getting these agents into the cell and reaching the target once inside.

Torchilin, the study’s principal investigator, is the director of the Center for Pharmaceutical Biotechnology and Nanomedicine (CPBN). His research expertise is in the area of drug delivery systems using nanotechnology as a way to treat cancer and other diseases.

Nanomedicine, the medical application of nanotechnology, holds tremendous promise as a way to improve drug delivery systems. Pharmaceutical scientists are creating targeted drug delivery systems using nanoparticles that will allow the drugs or DNA to enter the cell and reach the intended target and exert their therapeutic function. The success of these agents once in the cell, however, is compromised because of cellular activities and functions, such as lysosomal degradation, which can alter the drug or the DNA and can make them ineffective.

The main objectives of this research project include developing the process of getting these pharmaceutical agents into the cell, identifying the target once inside the cell and protecting the integrity and activity of the drug or the DNA. Developing a platform for the creation of drug delivery systems capable of intracellular penetration, bypassing the cell wall and membrane, and targeting specific organelles, such as the mitochondria or lysosomes, will improve both the delivery of drugs and DNA and therapeutic outcomes for diseases such as cancer, lysosomal storage diseases, and diseases associated with genome dysfunctions.


Vladimir Torchilin, chair of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University’s Bouvé College of Health Sciences.

“The ultimate goal of this research is to solve the extremely important and challenging problem of intracellular organelle-specific drug delivery, which will dramatically increase the efficacy of many therapies,” said Torchilin.

“We expect this research will lead to the development of a novel platform for targeted drug and gene delivery within cells and for provoking the effective apoptosis of cancer cells” he added. “Our hope is that this platform can be used to treat as many diseases as possible.”

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

NEW PRODUCTS

MKS introduces the I-Series family of high flow mass flow controllers
02/25/2015MKS Instruments, Inc., a global provider of technologies that enable advanced processes and improve productivity, has introduced th...
TMC introduces stage-base 450 with voice coil technology
02/10/2015TMC, a developer of high-performance vibration and motion cancellation technology, has introduced Stage-Base 450, its next generation of frame-m...
Entegris launches Dispense System optimized for 3D and MEMS applications
02/03/2015Entegris, Inc. announced the latest addition to its IntelliGen family of two-stage dispense technologies used in microelectronic...